Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Klinic collaborates directly with your insurer to maximize coverage, and also connects you to savings programs and copay assistance if accessible
REDEFINE 4: The Tirzepatide Test The results that attracted the greatest market attention came from REDEFINE 4, an 84-week open-label Phase 3 trial reported in February 2026, in which CagriSema was pitted directly against tirzepatide 15 mg, the highest approved dose of Eli Lillys Zepbound
People, especially children, should be watched for signs of decreased sweating and fever, especially in hot temperatures
Retatrutides rates are a bit higher at top doses
